Headlines about Insys Therapeutics (NASDAQ:INSY) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insys Therapeutics earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 44.395679808104 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s rankings:

Shares of Insys Therapeutics (INSY) traded down 0.65% on Wednesday, hitting $9.20. 49,601 shares of the stock traded hands. The stock’s market cap is $668.80 million. Insys Therapeutics has a one year low of $8.70 and a one year high of $16.00. The company’s 50 day moving average is $10.21 and its 200 day moving average is $11.37.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The firm’s revenue was down 38.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 EPS. On average, equities analysts forecast that Insys Therapeutics will post ($0.29) EPS for the current year.

INSY has been the topic of a number of recent research reports. Piper Jaffray Companies lowered shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $20.00 to $10.00 in a report on Wednesday, May 10th. Royal Bank Of Canada set a $16.00 target price on shares of Insys Therapeutics and gave the company a “buy” rating in a report on Saturday, June 3rd. Jefferies Group LLC restated a “buy” rating and issued a $14.00 target price on shares of Insys Therapeutics in a report on Friday, June 9th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Finally, BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Insys Therapeutics currently has an average rating of “Hold” and an average target price of $13.25.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-insys-therapeutics-insy-stock-price.html.

In other news, CEO Saeed Motahari purchased 5,500 shares of Insys Therapeutics stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $8.92 per share, for a total transaction of $49,060.00. Following the acquisition, the chief executive officer now directly owns 15,400 shares in the company, valued at $137,368. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of Insys Therapeutics stock in a transaction dated Friday, August 11th. The shares were purchased at an average price of $8.93 per share, with a total value of $156,275.00. Following the completion of the acquisition, the insider now owns 31,982 shares in the company, valued at $285,599.26. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 28,400 shares of company stock valued at $265,275. 67.90% of the stock is owned by corporate insiders.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.